Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

– Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in the third quarter of 2025 –

– Top-line data from Phase 2 clinical trial of verekitug in patients with severe asthma now expected in the first half of 2026 –

Read more at globenewswire.com